Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Portfolio Pulse from Vandana Singh
Intellia Therapeutics' stock fell 18.3% after releasing Phase 2 data for its gene therapy NTLA-2002, showing significant reduction in HAE attack rates. The 50 mg dose was selected for Phase 3 trials, expected to conclude by 2027.
October 24, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics' stock dropped 18.3% after releasing Phase 2 data for NTLA-2002, which showed promising results in reducing HAE attack rates. The 50 mg dose was chosen for Phase 3 trials, expected to conclude by 2027.
Despite promising Phase 2 results for NTLA-2002, Intellia's stock fell 18.3%. This could be due to market expectations not being met or concerns about the long timeline until Phase 3 completion in 2027.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100